Kario K, et al. - Researchers performed the SGLT2 inhibitor and ARB Combination theRapy in pAtients with diabetes and uncontrolled nocturnal hypertension (SACRA) study to investigate the changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy. In this multicenter, double-blind, parallel study, they randomized adult patients with type 2 diabetes mellitus and uncontrolled nocturnal hypertension receiving stable antihypertensive therapy including angiotensin receptor blockers to 12 weeks' treatment with empagliflozin 10 mg once daily or placebo. The addition of empagliflozin led to significant BP reductions without marked reductions in glucose among non-severely obese older diabetes patients with uncontrolled nocturnal hypertension compared to existing antihypertensive and antidiabetic therapy. In specific groups, use of SGLT2 inhibitors (eg those with nocturnal hypertension, diabetes, and high salt sensitivity) may help to decrease the risk of heart failure and cardiovascular mortality.